Palopegteriparatide Patent Expiration
Palopegteriparatide was first introduced by Ascendis Pharma Bone Diseases As
Palopegteriparatide Patents
Given below is the list of patents protecting Palopegteriparatide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Yorvipath | US12403182 | Liquid Pharmaceutical Formulations Of Pth Conjugates | Nov 12, 2042 | Ascendis Pharma Bone |
| Yorvipath | US11590207 | Dosage regimen for a controlled-release PTH compound | Sep 28, 2037 | Ascendis Pharma Bone |
| Yorvipath | US11759504 | PTH compounds with low peak-to-trough ratios | Sep 28, 2037 | Ascendis Pharma Bone |
| Yorvipath | US11857603 | PTH compounds with low peak-to-trough ratios | Sep 28, 2037 | Ascendis Pharma Bone |
| Yorvipath | US11890326 | Controlled-release PTH compound | Sep 28, 2037 | Ascendis Pharma Bone |
| Yorvipath | US11918628 | Controlled-release PTH compound | Sep 28, 2037 | Ascendis Pharma Bone |
| Yorvipath | US12295989 | Controlled-release PTH compound | Sep 28, 2037 | Ascendis Pharma Bone |
| Yorvipath | US12453778 | Incremental Dose Finding In Controlled-Release Pth Compounds | Sep 28, 2037 | Ascendis Pharma Bone |
| Yorvipath | US8906847 | Prodrug comprising a drug linker conjugate | Apr 30, 2031 | Ascendis Pharma Bone |
Palopegteriparatide's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Palopegteriparatide:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism | Ascendis Pharma Bone Diseases A/S | NA |
RECRUITING
(Aug 1, 2026)
| PHASE3 |
| A Study to Test the Effects and Safety of Palopegteriparatide in Adolescents With Long-term Hypoparathyroidism | Ascendis Pharma A/S | NA |
RECRUITING
(Jul 1, 2026)
| PHASE3 |